288. Autoimmune acquired coagulation factor deficiency
189 clinical trials,   219 drugs   (DrugBank: 29 drugs),   18 drug target genes,   26 drug target pathways

Searched query = "Autoimmune acquired coagulation factor deficiency", "Coagulation factor deficiency", "Factor XIII deficiency", "Factor VIII deficiency", "Acquired hemophilia A", "von Willebrand Disease", "Factor V deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04344860
(ClinicalTrials.gov)
February 1, 20219/4/2020Prevent Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN TrialProspective, Randomized Trial Comparing Recombinant Von Willebrand Factor (rVWF) Plus Tranexamic Acid vs. rVWF Alone to Reduce Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN TrialVon Willebrand Diseases;Postpartum HemorrhageDrug: Recombinant Von Willebrand factor;Drug: Tranexamic Acid Injection [Cyklokapron]Margaret RagniNULLNot yet recruiting18 YearsN/AFemale20Phase 3United States
2NCT04146376
(ClinicalTrials.gov)
October 12, 201929/10/2019Von Willebrand Factor in Pregnancy (VIP) StudyVon Willebrand Factor in Pregnancy (VIP) Study: A Multicenter Study of Wilate Use in Von Willebrand Disease for ChildbirthVon Willebrand DiseasesOther: Use of a postpartum diary and additional blood draws;Drug: VWF replacement therapy with Wilate;Drug: Tranexamic acid;Other: Use of a postpartum diary and additional blood draws.BloodworksMary M. Gooley Hemophilia Center;Ergomed;OctapharmaRecruiting18 YearsN/AFemale110United States
3NCT02606045
(ClinicalTrials.gov)
February 7, 20195/11/2015Minimize Menorrhagia in Women With Von Willebrand DiseaseProspective, Randomized, Crossover Trial Comparing Recombinant Von Willebrand Factor (rVWF) vs. Tranexamic Acid (TA) to Minimize Menorrhagia in Women With Von Willebrand Disease: The VWD Minimize StudyVon Willebrand DiseasesDrug: recombinant von Willebrand factor;Drug: tranexamic acidMargaret RagniUniversity of North Carolina;Duke UniversityRecruiting13 Years45 YearsFemale60Phase 3United States
4NCT01800435
(ClinicalTrials.gov)
October 201115/2/2013A Comparison Study of Bypassing Agent Therapy With and Without Tranexamic Acid in Haemophilia A Patients With InhibitorWhole Blood Clot Stability and Thrombin Generating Capacity Following Treatment With Bypassing Agents (BPA) With and Without and Tranexamic Acid (TXA) in Haemophilia A Patients With inhibitor-an In-vivo Prospective Crossover StudyHereditary Factor VIII Deficiency Disease With InhibitorDrug: aPCC, aPCC + TXA;Drug: rFVIIa, rFVIIa + TXAOslo University HospitalNULLCompleted18 Years65 YearsMale6Phase 4Norway
5NCT00111215
(ClinicalTrials.gov)
January 200118/5/2005Treatment and Management of Women With Bleeding DisordersTreatment and Management of Women With Bleeding DisordersMenorrhagia;Blood Coagulation Disorders;Blood Platelet Disorders;Von Willebrand Disease;Hematologic DiseaseDrug: Tranexamic Acid;Drug: Desmopressin AcetateCenters for Disease Control and PreventionNULLCompleted18 Years50 YearsFemale100N/AUnited States